Novel Alternatives to Chemotherapy in Advanced Disease: Gastrin Antibodies
Publisher
Springer London
Reference51 articles.
1. Fernandez E, La Vecchia C, Porta M, et al. Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer 1994; 15: 57 (6):786–92.
2. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82 (1):111–5.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (6):2403–13.
4. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7 (4):347–53.
5. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33:S18–22 (Suppl 1).